Advertisement

Topics

Oncogenic BRAF in cancer - Biotech, Pharma and Life Science Channel

03:28 EDT 19th October 2017 | BioPortfolio

Oncogenic BRAF can result from mutations in the BRAF gene, which may cause the protein to become overactive. The most common alteration in the BRAF gene leads to the BRAFV600E mutation. Mutations in the BRAF gene allow for BRAF to signal independently of upstream cues, and result in overactive downstream signaling via MEK and ERK. This, in turn, leads to excessive cell proliferation and survival, independent of growth factors.

Source: http://www.biooncology.com/research-education/braf/targeting

PubMed Articles [231 Associated PubMed Articles listed on BioPortfolio]

PAK Signaling Promotes Acquired Resistance to BRAF and MEK Inhibitors.

PAK signaling drives resistance to BRAF inhibition and dual BRAF/MEK inhibition via distinct mechanisms.

Copper Chelation Inhibits BRAFV600E-driven Melanomagenesis and Counters Resistance to BRAFV600E and MEK1/2 Inhibitors.

MEK1/2 and BRAFV600E inhibitors are used to treat BRAFV600E-positive melanoma, with other cancers under evaluation. Genetic perturbation of copper import or pharmacological reduction of copper with th...

Primary central nervous system malignant melanoma with leptomeningeal melanomatosis: a case report and review of the literature.

Leptomeningeal melanomatosis is an extremely rare variant of primary central nervous system (CNS) melanoma and has a poor prognosis and no standard treatment. Primary CNS melanoma is derived from the ...

Escaping BRAF inhibition: a "linc" with non-coding RNAs?

One of the major challenges in the field remains the defeat of resistance towards BRAF inhibition, mainly caused by the high heterogeneity and plasticity of melanoma cells. Understanding mechanisms of...

BRAF V600E mutation is a significant prognosticator of the tumour regrowth rate in brainstem gangliogliomas.

BRAF V600E mutations are progression factors in paediatric low-grade gliomas. Furthermore, a high percentage of paediatric brainstem gangliogliomas have BRAF V600E mutations. However, their clinical s...

Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.

Patients with BRAF(V600E)-mutated metastatic colorectal cancer (mCRC) have a poorer prognosis as well as resistance to anti-EGFR antibodies. However, it is unclear whether BRAF mutations other than BR...

Granuloma Annulare Secondary to Vemurafenib Therapy for Lung Adenocarcinoma.

Numerous cutaneous manifestations have been associated with use of BRAF inhibitors, including two previously reported cases of granuloma annulare (GA) eruptions associated with vemurafenib therapy. Bo...

Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data.

BRAF inhibitor vemurafenib achieved improved overall survival over chemotherapy and have been approved by the FDA and EMA for the treatment of BRAF-mutated metastatic melanoma. The aim of our retrospe...

The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients.

The spectacular outcomes of the phase III trials regarding nivolumab versus ipilimumab in fully resected stage IIIB/C-IV and of the combination of dabrafenib (D) plus trametinib (T) in BRAF-mutant sta...

KRAS and BRAF somatic mutations in colonic polyps and the risk of metachronous neoplasia.

High-risk features of colonic polyps are based on size, number, and pathologic characteristics. Surveillance colonoscopy is often recommended according to these findings. This study aimed to determine...

News Articles [91 Associated News Articles listed on BioPortfolio]

Targeting both BRAF and EGFR doubles progression-free survival in metastatic colorectal cancer

Recent successes in genetically targeted precision cancer medicines are improving outcomes in a number of cancers.  Ensuring patients undergo genomic […] The post Targeting both BRAF and EGFR d...

Targeting BRAF and EGFR Doubles Progression-free Survival in Metastatic Colorectal Cancer

Recent successes in genetically targeted precision cancer medicines are improving outcomes in a number of cancers.  Ensuring patients undergo genomic […] The post Targeting BRAF and EGFR Double...

Intezyne Closes Oversubscribed $10M Series A Financing to Drive Rapid Oncology Portfolio Development

Intezyne Closes Oversubscribed $10M Series A Financing to Drive Rapid Oncology Portfolio Development   News provided by Intezyne Technologies, Inc. Oct 06, 2017, 08:30 ET   TAMPA, Fla.,...

Cancer drug addiction is relayed by an ERK2-dependent phenotype switch

Observations from cultured cells, animal models and patients raise the possibility that the dependency of tumours on the therapeutic drugs to which they have acquired resistance represents a vulnerabi...

Carcinogen susceptibility is regulated by genome architecture and predicts cancer mutagenesis

The development of many sporadic cancers is directly initiated by carcinogen exposure. Carcinogens induce malignancies by creating DNA lesions (i.e., adducts) that can result in mutations if left unre...

PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas

Targeted BRAF inhibition (BRAFi) and combined BRAF and MEK inhibition (BRAFi and MEKi) therapies have markedly improved the clinical outcomes of patients with metastatic melanoma. Unfortunately, the e...

Highly Sensitive Assessment Of Common Somatic Mutations In Pulmonary Non-Small Cell Carcinoma With The MassARRAY® System

SAN DIEGO, Sept. 27, 2017 /PRNewswire/ -- Agena Bioscience today announced a comparative study published in PLOS ONE highlighting the use of its mass spectrometry-based platform and new, highly sensit...

Obstruction of BRAFV600E transcription by complementary PNA oligomers as a means to inhibit BRAF-mutant melanoma growth

Shuwen Biotech Receives CE Mark for EGFR Mutation PCR Kit for Lung Cancer

Deqing, China, September 18, 2017 / B3C newswire / -- Shuwen Biotech announced today that it has received CE-IVD marking for its EGFR real time PCR detection kit allowing the company to market its k...

BRAFV600 mutation BRaf protooncogene, serine/threonine kinase Inhibiotors Pipeline Insights, 2017 [Report Updated: 01092017] Prices from USD $1500

DelveInsight's, BRAFV600 mutation BRaf protooncogene, serine/threonine kinase InhibiotorsMechanism of action Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research ...

Events [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

NewGene Limited

The demand for testing individuals for genetic disorders or cancers that have arisen from acquired genetic variations is growing year on year.  This is being driven by advances in medical genet...

Clinical Trials [101 Associated Clinical Trials listed on BioPortfolio]

Expanded Access for Pembrolizumab (MK-3475)

This is an expanded access program (EAP) for patient with Melanoma and Glioblastoma who have progressed after prior Protocol therapy including Bevacizumab, Temozolomide ( TMZ ), Ipilimumab...

Phase I Study of INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.

This research study is studying a combination of drugs as a possible treatment for BRAF-mutant melanoma. The drugs involved in this study are: - Itacitinib (INCB039110) ...

Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer

This is a multicentric prospective non-randomized phase II trial, with two independent arms: one for patients with RAS mutation and one for patients with BRAFV600E mutation.

Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib

This is a multicenter, 2-arm open-label, randomized comparative phase II study. The objective of this trial is to prospectively evaluate whether a sequential approach with an induction per...

First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS

- The association of FOLFOX (5-fluoruracil, folinic acid, and oxaliplatin) and pan is a standard option for the first-line treatment of unresectable RAS and BRAF wt mCRC patient...

A Study Evaluating Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy

This study will evaluate the preliminary efficacy, safety, and pharmacokinetics of cobimetinib and atezolizumab in participants with advanced BRAF V600-WT, metastatic, or unresectable loca...

Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX-CRC Trial.

AVETUX is a single arm multicentric phase II investigator initiated trial conducted by the Arbeitsgemeinschaft Internistische Onkologie (AIO) in 11 German sites in patients with previously...

FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status

To estimate progression-free survival at one year in elderly patients with RAS/BRAF wild-type unresectable mCRC and good performance status treated with FOLFIRI + panitumumab as first-line...

Early Therapy Response Monitoring in Melanoma Patients Using PET/MRI

Therapeutic agents used in malignant melanoma treatment such as BRAF/MEK inhibitors and anti-CTLA-4/Anti-PD-1 antibodies go along with harmful side effects in a considerable proportion of ...

Expansion Study to Evaluate the Efficacy and Safety of HM95573 in BRAF, KRAS or NRAS Mutant Solid Cancers

This study evaluates the anti-tumor efficacy and safety of single agent HM95573 administered in patients with solid tumors harboring mutations in either BRAF, KRAS or NRAS gene.

Videos

None available.

Medical and Biotech [MESH] Definitions

None available.

Quick Search
Advertisement
 

Relevant Topics

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

review and buy Oncogenic BRAF in cancer market research data and corporate reports here

Channels Quicklinks